GLUE · Monte Rosa Therapeutics, Inc.

Track GLUE — free

$10.27 -0.23 (-2.19%)

Russell 2000 member Rebalance outlook locked

Market Cap

$1.00B

85.31M

Volume · Oct 5 1.75M Avg daily vol (3M) 1.3M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Q4 2024 earnings call transcript

call held Mar 20, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$28.73M

Trailing 12 months

Net income (TTM)

−$161.09M

Trailing 12 months

Revenue growth YoY

-61.3%

Year over year

Operating margin

-633.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-3.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$90.10M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+23.5%

Year over year · more shares

Price change (1Y)

+37.6%

Trailing year

Short interest

22.6%

Latest settlement · 17.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −42%

below

Price vs 50-day avg −29%

below

RSI (14) 24

oversold

MACD trend Negative

52-week position 17%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −27%

trailing

6-month return −40%

trailing

YTD return −33%

this year

Relative strength −52%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $15 › 200d $18 — 200d above 50d

Institutional flow Accumulating

+1% holders QoQ · +28 funds added

Insider flow Distributing

Net -$220.2K over 90 days · 100% sells

Short interest Rising

22.58% of float · ▲ +6.6% MoM · 17.1 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

194 holders — near 3-yr high, broad support

Squeeze score 74

high risk · 0–100

Fundamentals

Fair

Revenue growth +64%

Y/Y

Free cash flow $-27.5M

Quant / Vol

risk profile

Very High

Volatility 85%

annualized · 1-yr

Max drawdown −59%

past year

ATR 7.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−42% Bearish

Price vs 50-day avg

−29% Bearish

RSI (14)

24 Neutral

MACD trend

Negative Bearish

52-week position

17% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $15 › 200d $18 — 200d above 50d

Institutional flow Accumulating

+1% holders QoQ · +28 funds added

Insider flow Distributing

Net -$220.2K over 90 days · 100% sells

Short interest Rising

22.58% of float · ▲ +6.6% MoM · 17.1 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

194 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $7 Now $11 · 17% Range high $25

vs 200-day avg -42% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
GLUE Monte Rosa Therapeutics, Inc. this stock	$1.00B	-33.0%	+63.5%	—	22.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

194

% held: 109.3%
Net QoQ: +6.0M sh
Top holder: PRICE T ROWE ASSOCIATES I…

Held Float

View

Held by Funds

Fund positions

211

View

Short & Settlement

Short Interest Rising

Shares short

19.3M

Days to cover: 17.1d
Change: +1.2M sh

View

Short Volume

Short vol %

47%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

1.5K

Value: $21.2K
As of: Sep 2, 2026

View

Off-Exchange

Off-exchange %

41.4%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$220.2K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-38.6M

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 1, 2026
This year: 14

View

Proposed Sales

Value

$220.2K

Shares: 9.5K
Filed: Jul 16, 2026

View

Exempt Offerings

Offering

$95.0M

Filed: Mar 24, 2021

View

Earnings & Events

Webcasts

Last webcast

Feb 26, 2026

View

Performance

	5D	20D	120D	MTD	YTD
GLUE	-10.8%	-27.0%	-40.2%	-12.0%	-33.0%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-10.6%	-26.5%	-52.4%	-12.9%	-45.9%

Key facts CIK 1826457 CUSIP 61225M102 13F (30d) 2 filings 2 filers Visit website Investor relations

GLUE · Monte Rosa Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance